<DOC>
	<DOCNO>NCT00086593</DOCNO>
	<brief_summary>This 12-week study treatment chronic persistent symptom participant schizophrenia . Participants stable , optimal dose two atypical antipsychotic fulfill screen criterion randomize receive either FDA-approved drug placebo addition current treatment . Safety closely monitor vital sign , various test , blood urine sample .</brief_summary>
	<brief_title>Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Inclusion criterion : Diagnosed schizophrenia . Exhibits persistent positive symptom persist minimum 3 month prior screen . Continuously take 12 specific atypical antipsychotic minimum 3 month must stable dose least 1 month prior enter study . Participant legal guardian able understand sign consent form . Exclusion criterion : PANSS ( Positive Negative Syndrome Score ) total score increase decrease 20 % Screening Baseline visit . Predominant Axis I disorder schizophrenia within 6 month prior screen . History clinically significant unstable medical disorder treatment would interfere study . History autistic disorder another pervasive developmental disorder , organic brain disease , dementia , stroke , epilepsy history seizure require treatment ( include febrile seizure child ) , suffer traumatic head injury . Taking psychotropic primarily centrally active medication screening . Use antidepressant medication mood stabilizer within 1 month screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adjunctive</keyword>
	<keyword>atypical antipsychotic</keyword>
	<keyword>add-on</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>psychosis</keyword>
</DOC>